Indonesia Is Injecting $1.1 Billion Into BPJS Kesehatan as 52 Million Members Lapse on Premiums
The injection keeps hospital claims paid for two months. It does not change the arithmetic that created the gap.
By subject
FDA’s Surgical Robot Guidance Prefers Robotic Comparator Data, Which Mostly Means Measuring Challengers Against Intuitive
One test for every surgical robot, and by preferring robotic comparators it decides whose results set the score.
Qatar Became Foundayo’s Sixth Market as Lilly Claimed an Edge Over Oral Semaglutide 25 mg
Approvals market by market, and data built to shape the comparison with a Novo dose that has not launched.
IQWiG and LSE Authors Say EU Joint Clinical Assessments Could Become a Basis for US Price Talks
A debate about who sets the evidence bar, landing the same week Germany’s health ministry proposed lowering it.
The plan lowers the evidence bar at launch and moves the proof to later real-world data, where insurers doubt it exists.
The plan lowers the evidence bar at launch and moves the proof to later real-world data, where insurers doubt it exists.
Novo Paid $300 Million Upfront for a Weekly GLP-1/GIP Pill That Has Not Yet Entered Phase 1
Novo paid a clean, large upfront for a once-weekly pill whose convenience advantage it cannot yet prove in people.
AstraZeneca Puts $2 Billion Into Summit, Whose Drug Beat AstraZeneca’s Own Imfinzi in Biliary Cancer
AstraZeneca bought access to ivonescimab, not rights, and paid a premium to sit next to the drug that beat Imfinzi.
China Cleared Jaypirca in Frontline CLL on a Win Over Chemotherapy and Non-Inferiority to Ibrutinib
The label reaches frontline CLL, but against a modern BTK inhibitor the evidence so far is a response rate.
AbbVie’s Juvmo Won FDA Approval Three Days Before ICER Holds a Public Meeting on Its Value
AbbVie now has to name a price for Juvmo into a benchmark that ICER set before the drug was even approved.
Kodiak’s Zenkuda Put 54% of Wet AMD Patients on Six-Month Dosing, Four Years After an Extended-Dosing Miss
The molecule that failed on long intervals in 2022 now holds vision with most patients on six-month dosing.